RxDoctor Payments DataLook up a doctor →

Shayla Bergmann

Pediatric Hematology-Oncology · Beaufort, SCNPI 1730143645

Payments from drug & device makers

$2,168,129in general payments, 2019–2025

Across 657 payments — averaging $3300.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$599K
  • Takeda Pharmaceuticals U.S.A., Inc.$444K
  • Global Blood Therapeutics, Inc.$345K
  • Pfizer$281K
  • Novo Nordisk$219K
  • CSL Behring$106K
  • plus $174K from 16 others
$25,303in research payments, 2019–2025

Across 39 payments — averaging $648.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shire North American Group Inc$15K
  • Pfizer$8K
  • CSL Behring$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,168,129 in reported general payments places this provider in the 95th percentile of 32 pediatric hematology-oncology providers in South Carolina.

See all pediatric hematology-oncology providers in South Carolina

Other pediatric hematology-oncology in Beaufort

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →